Dataset Information

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.

ABSTRACT:

Background

Shared learnings from the early use of novel therapies can aid in their optimization. The recent introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]) for peanut allergy addresses a significant unmet need but also highlights the requirement for consideration of several factors by both prescribers and patients.

Objective

To provide guidance for prescribers of licenced peanut OIT to facilitate treatment delivery and improve outcomes.

Methods

Clinicians with experience of licenced peanut OIT (United States n = 6, United Kingdom n = 1) participated in a series of interviews and group discussions designed to elicit tips for successful implementation.

Results

Clinicians identified 8 tips that were considered the most relevant, practical, and impactful for prescribers of Peanut (Arachis hypogaea) Allergen Powder-dnfp: (1) preparing to provide treatment, (2) assessing the medical indication for treatment and (3) shared decision making, (4) staff education, (5) establishing office processes, (6) managing patient expectations and using anticipatory guidance, (7) optimising adherence and (8) maintaining flexibility throughout the treatment process. In addition, a range of supporting materials (e.g., checklists and action plans) are provided.

Conclusion

The introduction of a novel therapy often requires healthcare providers to modify or adopt practices to effectively employ the treatment. The provision of guidance based upon early real-world experiences of licenced peanut OIT may help inform clinical practice and improve treatment outcomes.

SUBMITTER: Portnoy J

PROVIDER: S-EPMC9088027 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.

Portnoy Jay J Ciaccio Christina E CE Beausoleil Janet J Du Toit George G Fineman Stanley S Tilles Stephen A SA Zhang June J Lawrence Claire C Yassine Mohamed M Mustafa S Shahzad SS

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20220509 1

<h4>Background</h4>Shared learnings from the early use of novel therapies can aid in their optimization. The recent introduction of peanut oral immunotherapy (peanut OIT; Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp]) for peanut allergy addresses a significant unmet need but also highlights the requirement for consideration of several factors by both prescribers and patients.<h4>Objective</h4>To provide guidance for prescribers of licenced peanut OIT to facilitate treatment delivery ...[more]

PMID: 35534909

Similar Datasets

Project description:ObjectiveTo compared the cost-effectiveness of coadministration of a probiotic adjuvant with peanut oral immunotherapy (PPOIT) with placebo (no treatment) in children with peanut allergy.DesignProspectively planned cost-effectiveness analysis alongside a randomised control trial.SettingThe Royal Children's Hospital, Melbourne, Australia.Participants56 children with peanut allergy aged 1-10 years at recruitment.InterventionA daily dose of probiotic Lactobacillus rhamnosus CGMCC 1.3724 (NCC4007) and peanut oral immunotherapy administered for 1.5 years.Main outcomes measuresCosts were considered from a healthcare system perspective and included costs of treatment delivery and adverse events. Effectiveness outcomes included rate of sustained unresponsiveness (SU) and quality-adjusted life years (QALYs). The cost-effectiveness of PPOIT versus placebo was analysed using patient-level data. Time horizon was 10 years from commencement of PPOIT treatment, comprising 1.5 years of treatment (actual data), 4 years of post-treatment follow-up (actual data), and 4.5 years of extrapolation thereafter (modelling).ResultsHealthcare cost per patient over 10 years was higher for PPOIT compared with placebo ($A9355 vs $A1031, p<0.001). Over half of the per patient healthcare cost (53%) in the PPOIT group was attributable to treatment delivery, while the remaining cost was attributable to adverse events. Both measures of effectiveness were superior in the PPOIT group: the average SU rate over 10 years was 54% for PPOIT versus 6% for placebo (p<0.001); QALYs over 10 years were 9.05 for PPOIT versus 8.63 for placebo (p<0.001). Overall, cost per year of SU achieved was $A1694 (range $A1678, $A1709) for PPOIT compared with placebo, and cost per additional QALY gained was $A19 386 (range $A19 024, $A19 774).ConclusionsCost per QALY gained using PPOIT compared with no treatment is approximately $A20 000 (£10 000) and is well below the conventional value judgement threshold of $A50 000 (£25 000) per QALY gained, thus deemed good value for money ($A1= £0.5 approximately).Trial registration numberAustralian New Zealand Clinical Trials Registry ACTRN12608000594325; Post-results.

Dataset Information

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.

Background

Objective

Methods

Results

Conclusion

Publications

Eight tips for the implementation of the first licenced peanut allergy oral immunotherapy into clinical practice.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets